Show Entire Article
I am not a numbers cruncher. In high school, for example, I elected to take what the Los Angeles Unified School District called "Algebra Experiences." It was a euphemism for, "If you can't hack Algebra 1 and 2 in a single semester, we'll spread it out over four semesters." And I still struggled with it.
So, thank goodness for the stock stat mavens here at CNBC.
On the eve of the 10-year anniversary of the dot-com bubble bursting they sliced and diced all sorts of data on share price performance since March 10, 2000.
Unfortunately, Genentech can't be measured because it isn't around anymore as an independent, publicly-traded company, but the rest of big biotech has performed pretty darn well over the past decade.
As of yesterday's close, Gilead Sciences' stock is up 950 percent. Celgene has grown 339 percent. Even shares of the currently embattled Genzyme nearly doubled in 10 years. The previously embattled Biogen Idec saw a one-third improvement in the value of its shares. Amgen, however, is off three percent.
When I tweeted some of those fun facts on Twitter earlier today, one of the people who follows me quickly replied with a comparison to the performance of a few big pharma stocks.
Page 1 of 2 | Next PageShow Entire Article
More Top Stories